Advances in nucleic acid-based cancer vaccines

Area of Science:

• Vaccinology
• Immunotherapy
• Oncology

Background:

• Nucleic acid vaccines, particularly mRNA vaccines, have become vital, as demonstrated by COVID-19 and RSV vaccines.
• The combination of mRNA neoantigen vaccines and immune checkpoint inhibitors (ICIs) shows efficacy in treating cancers like melanoma and pancreatic cancer.
• DNA vaccines offer stability and cost-effectiveness, potentially benefiting developing nations and overcoming mRNA vaccine challenges.

Purpose of the Study:

• To review recent advancements in mRNA and DNA-based cancer vaccines.
• To discuss the current developmental status of nucleic acid cancer vaccines.
• To highlight the potential of these vaccines as next-generation cancer immunotherapeutics.

Main Methods:

• Review of current literature on mRNA and DNA cancer vaccine technology.
• Analysis of clinical trial data for nucleic acid vaccines in oncology.
• Exploration of combination therapies involving neoantigen vaccines and ICIs.

Main Results:

• mRNA vaccines have achieved significant milestones in infectious disease and show promise in cancer therapy.
• DNA vaccines present advantages in stability and cost, with ongoing trials exploring their use in cancer treatment.
• Combination therapies of nucleic acid vaccines and ICIs are demonstrating efficacy in eliciting protective anti-cancer responses.

Conclusions:

• Nucleic acid vaccines represent a significant advancement in cancer immunotherapy.
• The combination of DNA or mRNA neoantigen vaccines with ICIs is a promising strategy for various cancer types.
• Further research and clinical trials are essential to fully realize the potential of nucleic acid-based cancer vaccines.